Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 23Recurrence 6Neoplasms 4Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Paraproteinemias 2Hematologic Diseases 2Corneal Diseases 2Carcinoma, Non-Small-Cell Lung 2Blood Protein Disorders 2Various Advanced Cancer 1Triple Negative Breast Neoplasms 1Proteostasis Deficiencies 1Pancreatic Neoplasms 1Neoplasm, Residual 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Glioblastoma 1Amyloidosis 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Proteostasis Deficiencies × daratumumab × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡